Precision is a Choice

Mrs Lam and Her Son's Story

"Thanks to MD 35 Panel, my son can live like a normal kid."

My son has been diagnosed with Type 1 diabetes at a young age so his life has always been a little different from his peers. Since receiving insulin treatment, he cannot leave the house without his insulin pen. He underwent many different therapies but his condition never improved much. 

It all changed when our endocrinologist suggested that he should get tested for Maturity Onset Diabetes of the Young (MODY) – a type of young-onset diabetes caused by a single gene mutation. While diabetes runs in our family, his condition does not exactly match typical clinical presentations seen in common types of diabetes. When he tested positive for a known MODY mutation, we realised he has been misdiagnosed as Type 1 diabetes all along. MD 35 Panel shed light on my son’s diagnosis and prompted our endocrinologist to change his treatment. Now my son uses oral medications to keep his blood sugar levels under control and rarely suffers episodes of low blood sugar. He can live normally despite MODY and is now able to follow his friends everywhere.

These stories are modified from some users' experiences and feedbacks. They are only used for illustrations without guarantee of the services meeting the expected outcomes.

Monogenic Diabetes Panel - MD 35

Decode the final mysteries of diabetes

Monogenic diabetes is a subtype of diabetes caused by a single gene mutation. Maturity Onset Diabetes of the Young (MODY) is a main form of monogenic diabetes and usually diagnosed in late childhood to adulthood. It affects 1-2% of patients with diabetes and about 4% of patients with diabetes diagnosed under the age of 30. The clinical presentation of MODY usually overlaps with other types of diabetes, making misdiagnosis common in people with MODY.

Target Groups

Diabetes Patients

People with young-onset diabetes, especially those who are diagnosed before the age of 40 with multiple generations of diabetes

Autoantibody negative and substantial endogenous C-peptide level with a disease duration of more than 3 years


How it helps

There are different types of MODY, and the most appropriate treatment can be determined by identifying the specific type of MODY. The classification of subtypes is essential in young people. Testing can help doctors make an important decision including changes in medications such as replacing insulin with oral drugs in some MODY patients. Patients can benefit from personalized treatment, be informed of their prognosis and family planning. Premarital screening is suggested for patients with MODY to inform them the risk of their future children inheriting the disease. Extended family screening and/or cascade screening is also recommended to advise patients' family members of their risk of inheriting MODY.


Request for MD 35 Test


  1. Shields BM, Shepherd M, Hudson M, McDonald TJ, Colclough K, Peters J, Knight B, Hyde C, Ellard S, Pearson ER, Hattersley AT. Population-Based Assessment of a
    Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients. Diabetes Care. 2017;40(8):1017-1025.

  2. Carroll RW, Murphy R. Monogenic Diabetes: A Diagnostics Algorithm for Clinicians. Genes. 2013;4(4):522-535

Unit 628, Biotech Centre 2,11 Science Park West Ave.,
Hong Kong Science Park,Shatin, N.T., Hong Kong

Tel: (852) 2809 2893


  • Facebook
  • Instagram
© 2020 GemVCare Ltd. All Rights Reserved.